Key Highlights

  • Oxford Biomedica (LSE:OXB) remains in focus on the FTSE 250 as investors assess whether the Business can deliver the 25-30% Revenue growth it is guiding for 2027.
  • FY2026 revenue guidance was cut in August to £180-200 million, from a previous £220-240 million, with EBITDA margins now expected in the mid-single digits excluding one-off costs.
  • The company signed a record 17 new clients in the first half of 2026, more than 30% above the total for the whole of 2025.
  • Revenue Backlog stands at around £193 million, with a non-risk-adjusted opportunity pipeline of roughly $713 million.
  • OXB reiterated its ambition to reach around £500 million of annual revenue by 2030 and at least double-digit EBITDA margins in 2027.

Why Oxford Biomedica (LSE:OXB) Is in Focus Today

Oxford Biomedica (LSE:OXB), the Oxford-based contract development and Manufacturing organisation (CDMO) specialising in cell and gene therapies, continues to attract attention on 3 November 2026 as investors debate whether the shares have priced in this year's disappointment. The stock fell sharply, by around 14.5% on the day, when the company cut its 2026 revenue guidance in August, and it has since been trying to rebuild momentum.

With the final weeks of the year approaching, the market is focused on two big questions: can OXB deliver within its revised 2026 range, and how much visibility does it have on the steep growth it is promising for 2027? Debate on Investment platforms and Social Media has centred on the company's record client wins and maturing customer base, contrasted with near-term profitability pressure and delays at its US site.

The August Guidance Reset

In its half-year trading update on 7 August 2026, OXB reduced its FY2026 revenue guidance to £180-200 million at constant currency. The company cited three main factors: deferrals and delayed timelines on selected programmes due to changes in client strategy or clinical data; a shift in procurement strategy and approval process at a larger client; and a six-month delay to the integration and ramp-up plan at its manufacturing Facility in Durham, North Carolina.

As a result, EBITDA margins for 2026 are expected to be in the mid-single digits excluding one-off costs, or the low single digits on a reported basis. The first manufacturing run at the Durham site is now under way.

Interim Results: Strong Commercial Momentum

OXB published its interim results on 22 September 2026, reiterating the revised guidance in full. First-half revenue rose about 9% to roughly £80 million, supported by continued Demand for its viral vector manufacturing services.

The standout figure was client acquisition. OXB signed a record 17 new clients in the first half, more than 30% above the total signed in all of 2025. Its client base is also maturing, with a growing share of late-stage and commercial programmes, which typically bring larger and more predictable manufacturing volumes. The company highlighted a revenue backlog of around £193 million and a non-risk-adjusted opportunity pipeline of approximately $713 million.

OXB also reaffirmed its commercial Supply agreement with Bristol Myers Squibb for lentiviral vectors supporting BMS's CAR-T portfolio. In August, Eric Schmidhäuser joined as Chief Operating Officer, strengthening the Leadership team under Chief Executive Frank Mathias.

Medium-Term Targets Unchanged

Importantly for the investment case, Oxford Biomedica (LSE:OXB) left its medium-term targets unchanged. The company continues to guide to revenue growth of 25-30% in 2027, a return to at least double-digit EBITDA margins, and an ambition to reach around £500 million of annual revenue by 2030 as Operating Leverage improves across its global network.

OXB has expanded its CDMO footprint across the UK, US and Europe, giving it multi-site capacity for lentiviral, adeno-associated viral and other vector types. The strategy is to become a leading global, quality- and innovation-led partner for cell and gene therapy developers.

Analyst Sentiment

Despite the guidance cut, several Brokers maintained buy or outperform ratings, with targets cited in a range of around 950p to 1,140p, well above current levels. Analysts acknowledged that near-term forecasts and sentiment would be under pressure but pointed to solid revenue coverage and the Long-term Growth opportunity in cell and gene therapy manufacturing.

The Cell and Gene Therapy Market

Cell and gene therapies offer potentially curative treatments for cancers and genetic diseases, but they are complex and expensive to manufacture. Many biotech companies outsource production to specialist CDMOs such as OXB. However, the sector is sensitive to biotech funding conditions, clinical trial outcomes and regulatory decisions, which can lead to lumpy and unpredictable orders, as seen in 2026.

Key Risks

Risks include further client programme delays or cancellations, concentration of revenue among a small number of large clients, execution risk at the Durham site, competition from larger CDMOs, and the company's ongoing operating losses. Biotech funding conditions also influence demand for outsourced manufacturing.

What Investors Are Watching Next

Investors will watch for a year-end trading update in early 2027 confirming FY2026 revenue within the £180-200 million range, progress on ramping up the Durham facility, new client contract announcements and conversion of the pipeline into firm orders. Evidence that 2027 growth of 25-30% is well supported by contracted revenue will be key to restoring confidence. Updates on margins and Cash Flow will also be closely tracked.